Bailard’s Globus Medical GMED Stock Holding History

Bailard’s Portfolio GMED Stock Details GMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,411	Closed	-$222K	–	708
2020 Q4	$222K	Buy	+3,411	New	+$196K	0.01%	533

Other funds holding GMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Bailard's GMED Position: Q1 2021 in Review

Bailard sold out of Globus Medical (GMED) in Q1 2021, closing a stake of 3,411 shares — an estimated $222K sold.

Bailard first reported a position in GMED in Q4 2020 and held it in 1 quarter. The position peaked at $222K in Q4 2020. 345 funds tracked by Wall St. Rank hold GMED as of Q1 2021.

Bailard reported no remaining Globus Medical position as of Q1 2021 after selling out during the quarter.
Bailard sold 3,411 Globus Medical shares in Q1 2021, an estimated $222K.
Bailard first reported a position in Globus Medical in Q4 2020 and held it in 1 quarter.
Bailard's Globus Medical position peaked at $222K in Q4 2020.
345 funds tracked by Wall St. Rank held Globus Medical as of Q1 2021.

Based on Bailard's 13F filing for Q1 2021, filed 13 May 2021.